Maxim Group Maintains Medicus Pharma(MDCX.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsFeb 19 08:34 ET · Ratings

Medicus Pharma Ltd Poised for Growth: Buy Rating Reaffirmed Amid Promising Developments and Upcoming Catalysts

TipRanksFeb 19 08:05 ET · Ratings

Promising Phase 2 Study and Innovative Approach Boost Confidence in Medicus Pharma Ltd.

TipRanksFeb 15 13:05 ET

Medicus Pharma Expects Interim Data From Phase 2 Skin Cancer Trial by Quarter-end | NASDAQ:MDCX, TSX-V:MDCX

Proactive InvestorsFeb 14 08:40 ET

Medicus Pharma Advances Phase 2 BCC Clinical Study With FDA Submission Plans

TipRanksFeb 14 08:07 ET

Express News | Medicus Pharma Ltd. Announce That Its Phase 2 Clinical Study (SKNJCT-003) Which Is Currently Underway In Nine Clinical Sites In United States, Has Now Randomized More Than 50% Of 60 Patients Expected To Be Enrolled In The Study

BenzingaFeb 14 07:32 ET

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

newsfileFeb 14 07:30 ET

Medicus Pharma Announces Equity Deal, Shifts Focus to Nasdaq | NASDAQ:MDCX, TSX-V:MDCX

Proactive InvestorsFeb 11 09:32 ET

Medicus Pharma Announces Standby Equity Purchase Deal, To Delist From TSX Venture Exchange

RTTNewsFeb 11 08:42 ET

Medicus Pharma Brief: Says Has Entered Into Standby Equity Purchase Agreement and Announced Intention to Voluntarily Delist From the TSX Venture Exchange (TSXV)

MT NewswiresFeb 11 08:30 ET

Medicus Pharma Secures $15M Equity Purchase Agreement With Yorkville Advisors

BenzingaFeb 11 07:33 ET

Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk

WSJFeb 10 10:43 ET

Medicus Pharma Ltd. Announces Change of Auditor

TipRanksDec 26, 2024 08:27 ET

Medicus Pharma Ltd: Innovative D-MNA Product Positions Company for Success With Favorable Buy Rating

TipRanksDec 24, 2024 06:25 ET · Ratings

Brookline Capital Initiates Medicus Pharma(MDCX.US) With Buy Rating, Announces Target Price $12

Moomoo NewsDec 24, 2024 05:31 ET · Ratings

Medicus Pharma Initiated With a Buy at Brookline

TipRanksDec 24, 2024 05:10 ET · Ratings

Maxim Group Initiates Coverage On Medicus Pharma With Buy Rating, Announces Price Target of $10

BenzingaDec 17, 2024 08:57 ET · Ratings

Medicus Pharma Analyst Ratings

BenzingaDec 17, 2024 08:56 ET · Ratings

Maxim Group Initiates Medicus Pharma(MDCX.US) With Buy Rating, Announces Target Price $10

Moomoo NewsDec 17, 2024 08:31 ET · Ratings

Express News | Medicus Pharma Shares Are Trading Higher After the Company Its INAD File No.013880 Was Used as Part of a Major Species Designation From the FDA

BenzingaDec 12, 2024 08:27 ET